Sterne Kessler Goldstein Fox
Paul A. Ainsworth
 

Mind + Muscle

Paul A. Ainsworth

Director

 
  • Paul A. Ainsworth
  • p 202.772.8783
  • f 202.371.2540
  • painsworth@skgf.com

  • v-card

Mr. Ainsworth is a Director in the Litigation Group. His practice is focused on representing patent owners in enforcement proceedings and in representing pharmaceutical industry clients in patent litigation arising under the Hatch-Waxman Act. He has represented clients in patent cases in federal courts and before the United States International Trade Commission. He also served as counsel in numerous inter partes review proceedings on behalf of clients involved in parallel district court and USPTO proceedings. Among Mr. Ainsworth's clients include industry leaders in the pharmaceutical, medical devices, chemical manufacturing, consumer products, electronics, and e-commerce industries.

Mr. Ainsworth began his legal career as a law clerk for the Honorable Sue L. Robinson, United States District Judge, District of Delaware. Since his clerkship, he has built his practice around representing clients in complex, civil litigation. Mr. Ainsworth has an extensive track record representing patent owners in cases brought to enforce, protect, and monetize their intellectual property rights. He has unique breadth and depth in the field of Paragraph IV litigation, having represented both leading generic and innovator companies in district court and USPTO proceedings. He leverages this experience to develop and implement creative case strategies to achieve his client's business objectives.

Mr. Ainsworth was named a Rising Star in Patent Litigation by D.C. Super Lawyers in 2014. In addition to his patent litigation practice, he has also represented leading civil rights organizations on state and federal civil rights issues. In 2011, the National LGBT Bar Association named Mr. Ainsworth one of the “Best LGBT Lawyers Under 40” in recognition of both his accomplishments as a patent litigator and his contributions to the advancement of LGBT civil rights.

 

Representative Hatch-Waxman Matters

  • Salix Pharmaceuticals, Inc. v. Novel Laboratories, Inc., (D. Del.) (counsel for Novel Laboratories in Hatch-Waxman litigation concerning a treatment for ulcerative colitis—Apriso®)
  • IntelGenx Corp. v. Wockhardt Bio, AG, (D.N.J.) (counsel for IntelGenx in Hatch-Waxman litigation concerning a treatment for major depression—Forfivo®)
  • Helsinn Healthcare S.A. v. Aurobindo Pharma Ltd., (D. Del.) (counsel for Aurobindo in Hatch-Waxman litigation concerning an anti-nausea medication—Aloxi ®)
  • Alcon Pharmaceuticals Ltd. v. Apotex, Inc., (D. Del.) (counsel for Apotex in Hatch-Waxman litigation concerning a treatment for bacterial conjunctivitis--Vigamox®)
  • Galderma Laboratories Inc. et al v. Amneal Pharmaceuticals, LLC et al., (D. Del.) (counsel for Amneal in Hatch-Waxman litigation concerning a treatment for rosacea--Oracea®)
  • Abbott Laboratories et al v. Amneal Pharmaceuticals, LLC et al., (D. Del.)(counsel for Amneal in Hatch-Waxman litigation concerning a treatment for hyperlipidemia--Niaspan®)
  • AstraZeneca AB et al. v. Torrent Pharmaceuticals Ltd. et al., (D.N.J.) (counsel for Torrent in Hatch-Waxman litigation concerning a treatment for gastroesophageal reflux disease—Nexium®)
  • Reckitt Benckiser LLC v. Amneal Pharmaceuticals, LLC et al. (D.N.J.) (counsel for Amneal in Hatch-Waxman litigation concerning a dextromethorphan-based cough medication--Delsym®)
  • comScore, Inc. v. The Nielsen Company, (E.D. Va.) (counsel for comScore in multi-case litigation concerning internet audience measurement technologies)
  • Medeva Pharma Suisse A.G. et al v. Roxane Laboratories, Inc., (D.N.J); Medeva Pharma Suisse A.G. et al. v. Par Pharmaceuticals et al. (D.N.J) (counsel for patentee and licensee in a multi-case Hatch-Waxman litigation concerning a treatment for ulcerative colitis–Asacol®)
  • Shire LLC v. Watson Laboratories, Inc., (S.D.N.Y)(S.D. Fla) (counsel for patentee in a Hatch-Waxman litigation concerning a treatment for attention deficit hyperactivity disorder – Adderall XR®)
  • Janssen Pharmaceutica et al v. Barr Laboratories, Inc. et al., (D.N.J.); Janssen Pharmaceutica et al v. KV Pharmaceuticals, Inc. et al., (D.N.J.); Janssen Pharmaceutica et al v. Sandoz Pharmaceuticals, Inc. et al (D.N.J.) (counsel for patentee in multi-case Hatch-Waxman litigation concerning a treatment for symptoms of Alzheimer’s dementia—Razadyne ER®)

Other Representative Matters

  • In re Lithium Silicate Materials and Products Containing the Same, ITC Investigation No 337-TA-911  (counsel for Complainant Ivoclar Vivadent AG in an ITC investigation pertaining to lithium silicate-based dental prostheses)
  • Butamax Advanced Biofuels LLC v. Gevo, Inc., IPR 2013-00214, IPR 2013-00215 (counsel for petitioner in proceeding challenging the patentability of certain biofuel manufacturing patents).
  • In re Certain Video Game Machines and Related Three-Dimensional Pointing Devices, ITC Investigation No 337-TA-658 (counsel for respondent Nintendo in an ITC investigation concerning television interactive program guide and 3D pointing device technologies)
  • comScore, Inc. v. The Nielsen Company, (E.D. Va.) (counsel for comScore in multi-case litigation concerning internet audience measurement technologies)
  • Automated Tracking Solutions, LLC v. Awarepoint Corp., (E.D. Va.); Automated Tracking Solutions, LLC v. Teletracking Technologies, Inc. et al. (E.D. Va) (counsel for patentee in multi-case litigation relating to radio frequency identification (RFID) technology)
  • Asentinel LLC v. Cass Information Systems, (W. D. Tenn.)  (counsel on behalf of Asentinel in litigation involving telecommunications expense management software)
  • Representative Matters

      Representative Hatch-Waxman Matters

      • Salix Pharmaceuticals, Inc. v. Novel Laboratories, Inc., (D. Del.) (counsel for Novel Laboratories in Hatch-Waxman litigation concerning a treatment for ulcerative colitis—Apriso®)
      • IntelGenx Corp. v. Wockhardt Bio, AG, (D.N.J.) (counsel for IntelGenx in Hatch-Waxman litigation concerning a treatment for major depression—Forfivo®)
      • Helsinn Healthcare S.A. v. Aurobindo Pharma Ltd., (D. Del.) (counsel for Aurobindo in Hatch-Waxman litigation concerning an anti-nausea medication—Aloxi ®)
      • Alcon Pharmaceuticals Ltd. v. Apotex, Inc., (D. Del.) (counsel for Apotex in Hatch-Waxman litigation concerning a treatment for bacterial conjunctivitis--Vigamox®)
      • Galderma Laboratories Inc. et al v. Amneal Pharmaceuticals, LLC et al., (D. Del.) (counsel for Amneal in Hatch-Waxman litigation concerning a treatment for rosacea--Oracea®)
      • Abbott Laboratories et al v. Amneal Pharmaceuticals, LLC et al., (D. Del.)(counsel for Amneal in Hatch-Waxman litigation concerning a treatment for hyperlipidemia--Niaspan®)
      • AstraZeneca AB et al. v. Torrent Pharmaceuticals Ltd. et al., (D.N.J.) (counsel for Torrent in Hatch-Waxman litigation concerning a treatment for gastroesophageal reflux disease—Nexium®)
      • Reckitt Benckiser LLC v. Amneal Pharmaceuticals, LLC et al. (D.N.J.) (counsel for Amneal in Hatch-Waxman litigation concerning a dextromethorphan-based cough medication--Delsym®)
      • comScore, Inc. v. The Nielsen Company, (E.D. Va.) (counsel for comScore in multi-case litigation concerning internet audience measurement technologies)
      • Medeva Pharma Suisse A.G. et al v. Roxane Laboratories, Inc., (D.N.J); Medeva Pharma Suisse A.G. et al. v. Par Pharmaceuticals et al. (D.N.J) (counsel for patentee and licensee in a multi-case Hatch-Waxman litigation concerning a treatment for ulcerative colitis–Asacol®)
      • Shire LLC v. Watson Laboratories, Inc., (S.D.N.Y)(S.D. Fla) (counsel for patentee in a Hatch-Waxman litigation concerning a treatment for attention deficit hyperactivity disorder – Adderall XR®)
      • Janssen Pharmaceutica et al v. Barr Laboratories, Inc. et al., (D.N.J.); Janssen Pharmaceutica et al v. KV Pharmaceuticals, Inc. et al., (D.N.J.); Janssen Pharmaceutica et al v. Sandoz Pharmaceuticals, Inc. et al (D.N.J.) (counsel for patentee in multi-case Hatch-Waxman litigation concerning a treatment for symptoms of Alzheimer’s dementia—Razadyne ER®)

      Other Representative Matters

      • In re Lithium Silicate Materials and Products Containing the Same, ITC Investigation No 337-TA-911  (counsel for Complainant Ivoclar Vivadent AG in an ITC investigation pertaining to lithium silicate-based dental prostheses)
      • Butamax Advanced Biofuels LLC v. Gevo, Inc., IPR 2013-00214, IPR 2013-00215 (counsel for petitioner in proceeding challenging the patentability of certain biofuel manufacturing patents).
      • In re Certain Video Game Machines and Related Three-Dimensional Pointing Devices, ITC Investigation No 337-TA-658 (counsel for respondent Nintendo in an ITC investigation concerning television interactive program guide and 3D pointing device technologies)
      • comScore, Inc. v. The Nielsen Company, (E.D. Va.) (counsel for comScore in multi-case litigation concerning internet audience measurement technologies)
      • Automated Tracking Solutions, LLC v. Awarepoint Corp., (E.D. Va.); Automated Tracking Solutions, LLC v. Teletracking Technologies, Inc. et al. (E.D. Va) (counsel for patentee in multi-case litigation relating to radio frequency identification (RFID) technology)
      • Asentinel LLC v. Cass Information Systems, (W. D. Tenn.)  (counsel on behalf of Asentinel in litigation involving telecommunications expense management software)
  • Admissions
      • District of Columbia

      • Maryland

  • Education
    • J.D., The College of William and Mary

    • B.A., Political Science, The George Washington University